Shandong Linuo Pharmaceutical Co., Ltd. announced that it will receive CNY 200,000,000 in an equity round of funding on January 3, 2024. The transaction will include participation from returning investor Shandong Keyuan Pharmaceutical Co., Ltd., to retain the majority stake in the company. The investor company will use CNY 30,642,900 of raised funds, and CNY 169,357,100 of own funds to fund the transaction.

The company will add CNY 130,000,000 to the registered capital. Post-completion of the transaction the registered capital of the company will increase from CNY 170,000,000 to CNY 300,000,000. This has been approved in the 12th meeting of the 3rd directorate and the 9th meeting of the 3rd supervisory board of the investor's company.

The transaction is subject to the shareholders? approval.